Cargando…
MEDB-87. Transcriptome-driven drug repurposing in group 3 medulloblastoma
Across the molecular spectrum of medulloblastoma (MB), group 3 (G3) tumors are the most aggressive with <50% five-year survival, the lowest of all MB subgroups. G3 MB tumors are characterized by frequent metastases at diagnosis, unique methylation profiles, MYC amplification, and i17q, but these...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165013/ http://dx.doi.org/10.1093/neuonc/noac079.461 |